The FDA is preparing to make a decision that could turbocharge a market already fueled by influencers, online vendors, and bodybuilding lore. This week, the agency released plans to hold a meeting with independent advisers in July to review whether some U.S. pharmacies should be allowed to manufacture certain peptides, including BPC-157, TB-500, and KPV.

If that door opens, people who are already seeking these injections through gray-market channels may switch to “legit” supply chains. And that matters, because for many of these peptides, the clinical evidence is limited and the safety picture is even less clear. The FDA’s review is coming despite the agency’s prior actions in 2023, when it banned several peptides, including BPC-157, GHK-Cu, KPV, and ipamorelin, from being produced in the U.S. by compounding pharmacies due to “significant safety risks.”

To understand why this is a big lever, you have to know what’s being sold as “peptides” in the first place. A peptide is a chain of two or more amino acids, building blocks of proteins. Your body makes peptides naturally, and some familiar ones are also peptides, like insulin and human growth hormone. Even GLP-1 drugs are in the peptide universe: semaglutide is an active ingredient in GLP-1 receptor agonist drugs such as Ozempic and Wegovy, which are FDA-approved for type 2 diabetes and for weight loss.

That mainstream success helped normalize peptide injections. A criminologist studying enhancement drug use, Luke Turnock of the University of Lincoln, says the “real cultural tipping point” seems to have been around 2022, when GLP-1s blew up for weight loss. Once it became obvious that approved diabetes drugs could also drive weight loss, injecting drugs became more “normalized.” In parallel, fitness and longevity communities fed a different narrative: that certain peptides are natural, derived from or modeled on naturally occurring molecules, and therefore safer or more targeted.

But the term “peptides” is now operating like a catchall. Turnock points out that online retailers and the public often use “peptides” for any chemical taken for well-being, energy, exercise recovery, and more. Flynn McGuire, who studies sports medicine at the University of Utah, adds the core linguistic trap: “Because it’s 'natural,' it is better or different, even though they’re just drugs.” In other words, the branding argues for difference while the regulatory reality treats them as drugs with the same need for proof.

The demand signal is not subtle. Orthopedic surgeon Omar Rahman, who practices at Pacific Coast Sports Medicine in Los Angeles, says he has seen a spike in patients asking about peptides, often driven by the longevity and wellness space. Online communities reflect that interest too: the subreddit r/peptides has more than 70,000 weekly visitors, and r/biohackers, which often hosts discussions on peptides, has more than 600,000. On TikTok, people share “stacks,” meaning combinations of injections tailored to goals like muscle-building and “exercise recovery,” or even increased brainpower and a better tan. The “stack” concept is a key reason the evidence gap becomes an even bigger operational risk.

One example: BPC-157 is promoted as a way to stimulate multiple cellular pathways involved in blood vessel formation, cell growth, muscle repair, and inflammation. McGuire, Cushman, and colleagues published a review last year on BPC-157 and found most evidence for health effects came from rodent studies, with only three small pilot studies looking at BPC-157 use in humans. Many people respond to that limited dataset with more complexity. The “Wolverine” stack combines BPC-157 with TB-500, a peptide supposed to promote healing, even though it has even less research behind it. Add GHK-Cu and KPV and the stack becomes “glow” or “KLOW.” People claim GHK-Cu increases wound healing, decreases scarring, and helps regenerate collagen, while KPV is said to reduce inflammation.

Here’s where executives should pay attention: several of these peptides are already banned from U.S. compounding production. GHK-Cu, for instance, is an FDA-approved ingredient in topical antiaging cosmetics, but it is currently banned as an injectable due to safety concerns, including the risk of immune reactions caused by impurities. For muscle-building, ipamorelin and CJC-1295 are advertised as stimulating growth hormone release, but they have little clinical evidence. Some users even stack ipamorelin with GLP-1 drugs, trying to lose fat while building muscle, yet “the effects of taking these injections together have not been studied.”

That leads to the operational core of this story: trial data for most peptides is thin, but dosing and stacking decisions are not cautious. Cushman, a sports medicine doctor at the University of Utah, says FDA-approved drugs are tested and reviewed for both efficacy and safety. With these peptides, the effects are often anecdotal, the doses are also not standardized, and there’s very little information on what happens if they are combined. Compounding pharmacies, Rahman notes, have become part of the supply chain through which people get these products, but variability in sourcing is a major concern, especially around purity, dosing consistency, and overall quality control.

So what changes if the FDA grants the “lift” that RFK Jr. proposed? On February 27, Robert F. Kennedy, Jr., secretary of the Department of Health and Human Services, proposed legalizing the compounding of 14 peptides. The FDA appears poised to grant part of that wish, with the July meeting signaling a potential pathway back toward broader manufacturing permissions. If that happens, a “flood of people could start using the drugs,” regardless of safety uncertainties. For boards, investors, and operators in health, wellness, and consumer biotech-adjacent markets, this is the classic fast growth vs. slow evidence problem. Demand can move in weeks; clinical validation and safety clarity move in years. The strategic stake is whether the compliance and risk posture can keep up with the market’s speed.